ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Janus kinase (JAK)"

  • Abstract Number: 849 • 2014 ACR/ARHP Annual Meeting

    Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension up to 6 Years

    J. Wollenhaupt1, J. Silverfield2, E.B. Lee3, S.P. Wood4, K. Terry4, H. Nakamura5, K. Kwok6, A. Anisfeld6, C. Nduaka4, R. Riese4 and L. Wang4, 1Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, 2Healthpoint Medical Group, Tampa, FL, 3Seoul National University, Seoul, South Korea, 4Pfizer Inc, Groton, CT, 5Pfizer Inc, Tokyo, Japan, 6Pfizer Inc, New York, NY

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we report tofacitinib safety, tolerability, and durability of response…
  • Abstract Number: 461 • 2014 ACR/ARHP Annual Meeting

    Comprehensive Summary of the Efficacy and Safety of Tofacitinib 5mg Twice Daily in Patients with Rheumatoid Arthritis and an Inadequate Response to Disease-Modifying Antirheumatic Drugs

    P. Bird1, W. Bensen2, B. El-Zorkany3, J. Kaine4, B.H. Manapat-Reyes5, V. Pascual-Ramos6, D. Witcombe7, A. Anisfeld8, K. Soma9, R. Zhang9 and K. Thirunavukkarasu7, 1Combined Rheumatology Practice, Sydney, Australia, 2St. Joseph's Healthcare, McMaster University, Hamilton, ON, Canada, 3Department of Rheumatology, Cairo University, Cairo, Egypt, 4Sarasota Arthritis Research Center, Sarasota, FL, 5Section of Rheumatology, Department of Medicine, University of the Philippines - Philippine General Hospital, Manila, Philippines, 6Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 7Pfizer Australia, Sydney, Australia, 8Pfizer Inc, New York, NY, 9Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib has been approved in the US and other countries at the recommended dose 5 mg BID in patients (pts) with rheumatoid arthritis (RA) and…
  • Abstract Number: 460 • 2014 ACR/ARHP Annual Meeting

    Analysis of Non-Melanoma Skin Cancer Across the Tofacitinib Rheumatoid Arthritis Clinical Program

    Jeffrey R. Curtis1, E.B. Lee2, G. Martin3, X. Mariette4, K.K. Terry5, Y. Chen6, J. Geier7, J. Andrews5, M. Kaur6, K. Kwok7 and C. Nduaka5, 1University of Alabama at Birmingham, Birmingham, AL, 2Seoul National University College of Medicine, Seoul, South Korea, 3Dermatology and Laser Center of Maui, Kihei, HI, 4Paris-Sud University, Paris, France, 5Pfizer Inc, Groton, CT, 6Pfizer Inc, Collegeville, PA, 7Pfizer Inc, New York, NY

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). The incidence of non-melanoma skin cancer (NMSC) in the tofacitinib…
  • Abstract Number: 465 • 2014 ACR/ARHP Annual Meeting

    18-Month Worldwide Post-Marketing Surveillance Experience of Tofacitinib

    S. Cohen1, Jeffrey R. Curtis2, Roy Fleischmann1 and Y. Chen3, 1Metroplex Clinical Research Center, Dallas, TX, 2University of Alabama, Birmingham, AL, 3Pfizer Inc, Collegeville, PA

    Background/Purpose: Post-marketing surveillance is an important part of monitoring adverse events (AEs) following the approval of new drugs. Tofacitinib is an oral Janus kinase inhibitor…
  • Abstract Number: 2822 • 2014 ACR/ARHP Annual Meeting

    Safety and Efficacy of Baricitinib through 128 Weeks in an Open-Label, Long-Term Extension Study in Patients with Rheumatoid Arthritis

    Edward C. Keystone1, Peter C. Taylor2, Mark C Genovese3, Douglas E. Schlichting4, Inmaculada De La Torre5, Scott D. Beattie4 and Terence Rooney4, 1University of Toronto, Mount Sinai Hospital, Toronto, ON, Canada, 2NDORMS, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, 3Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA, 4Eli Lilly and Company, Indianapolis, IN, 5AVDA. DE LA INDUSTRIA 30, Eli Lilly and Company, Alcobendas, Spain

    Background/Purpose: Baricitinib is an oral inhibitor of JAK1/JAK2 being investigated as a treatment for rheumatoid arthritis (RA).  In a phase 2b study, baricitinib treatment resulted…
  • Abstract Number: 39 • 2014 ACR/ARHP Annual Meeting

    Human CD14+ Monocytes Stimulated with a Combination of TNFα and IL-6 Differentiate into Osteoclast-like Cells with Bone-Resorption Activity

    Kazuhiro Yokota1, Kojiro Sato2, Yoshimi Aizaki2, Yuji Akiyama2 and Toshihide Mimura2, 1Department of Rheumatology & Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, 2Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan

    Background/Purpose Proinflammatory cytokines play an important role in bone destruction in rheumatoid arthritis (RA), as inferred by the efficacy of biologics. Previously, we reported that…
  • Abstract Number: 2489 • 2014 ACR/ARHP Annual Meeting

    Analysis of Early Neutropenia, Clinical Response, and Serious Infection Events in Patients Receiving Tofacitinib for Rheumatoid Arthritis

    V. Strand1, A. Dikranian2, J. Beal3, K. Kwok3, S. Krishnaswami4, S. Wood4 and C. Nduaka4, 1Biopharmaceutical Consultant, Portola Valley, CA, 2San Diego Arthritis Medical Clinic, San Diego, CA, 3Pfizer Inc, New York, NY, 4Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Post-baseline (BL) decreases in mean peripheral neutrophil count were…
  • Abstract Number: 1812 • 2014 ACR/ARHP Annual Meeting

    Investigation of the Sting/Interferon Pathway Activation in a Novel Vasculopathy and Pulmonary Syndrome

    Yin Liu1, Adriana Almeida de Jesus2,3, Bernadette Marrero4, Dan Yang5, Gina A. Montealegre Sanchez6, Steve Brooks7, Zuoming Deng8, Amy Paller9, Manfred Boehm5 and Raphaela Goldbach-Mansky6, 1Translational Autoinflammatory Disease Section, Office of the Clinical Director, NIAMS/NIH, Bethesda, MD, 2Translational Autoinflammatory Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, 3Translational Autoinflammatory Diseases Section, NIAMS/NIH, Bethesda, MD, 4Translational Autoinflammatory Disease Section, NIAMS/NIH, Bethesda, MD, 5Laboratory of Cardiovascular Regenerative Medicine, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, 6Translational Autoinflammatory Diseases Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, 7NIAMS/NIH, Bethesda, MD, 8Biodata Mining and Discovery Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, 9Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL

    Background/Purpose:  We have recently studied a group of patients with a prominent interferon (IFN) signature in the blood, distinct from IL-1 mediated autoinflammatory diseases. Six…
  • Abstract Number: 1537 • 2014 ACR/ARHP Annual Meeting

    Clinical Characteristics of RA Patients Newly Prescribed Tofacitinib Citrate (tofacitinib) in the United States after Food and Drug Administration Approval:  Results from the Corrona US Rheumatoid Arthritis Registry

    Arthur Kavanaugh1, George W. Reed2,3, Katherine C. Saunders2, Andrew S. Koenig4, Jamie Geier5, Joel M. Kremer6, Jeffrey D. Greenberg2,7 and Clifton O. Bingham III8, 1University of California San Diego, La Jolla, CA, 2Corrona, LLC., Southborough, MA, 3University of Massachusetts Medical School, Worcester, MA, 4Pfizer, Inc., Collegeville, PA, 5Pfizer, Inc., New York, NY, 6Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, 7Rheumatology, New York University School of Medicine, New York, NY, 8Johns Hopkins University, Baltimore, MD

    Background/Purpose: To provide initial characterization of the patients prescribed tofacitinib during the early period after United States (US) Food and Drug Administration (FDA) approval (11/6/2012).…
  • Abstract Number: 1514 • 2014 ACR/ARHP Annual Meeting

    An Analysis of in-Vitro Cytokine Inhibition Profiles of Tofacitinib and Other Janus Kinase Inhibitors at Clinically-Meaningful Concentrations

    M.E. Dowty, T.S. Lin, L. Wang, J. Jussif, B. Juba, L. Li, E. Moy and J.-B. Telliez, Pfizer Worldwide R&D, Cambridge, MA

    Background/Purpose: A number of Janus kinase (JAK) inhibitors are being actively investigated for treatment of rheumatoid arthritis (RA), including tofacitinib, baricitinib, filgotinib (GLPG0634), and decernotinib…
  • Abstract Number: 1691 • 2013 ACR/ARHP Annual Meeting

    The STAT1 Signaling Pathway In Giant Cell Arteritis

    Bjorn Hartmann1, Joyce Liao2, Michael H. Weisman3, Kenneth J. Warrington4, Jorg J. Goronzy1 and Cornelia M. Weyand5, 1Medicine: Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, 2Byers Eye Institute at Stanford, Stanford University, Palo Alto, CA, 3Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 4Division of Rheumatology, Mayo Clinic, Rochester, MN, 5Medicine, Stanford University School of Medicine, Stanford, CA

    Background/Purpose: In giant cell arteritis (GCA), CD4 T cells, macrophages and multinucleated giant cells form granulomatous lesions in the walls of medium and large arteries.…
  • Abstract Number: 1433 • 2013 ACR/ARHP Annual Meeting

    Lack Of Early Clinical Response To Treatment With Baricitinib Predicts Low Probability Of Achieving Long Term DAS28-ESR Low Disease Activity Or Remission In Patients With Rheumatoid Arthritis

    Edward Keystone1, MC Genovese2, Peter Taylor3, Baojin Zhu4, Scott D. Beattie4, Stephanie de Bono4, Terence Rooney4, Douglas E. Schlichting4 and William Macias4, 1University of Toronto, Toronto, ON, Canada, 2Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA, 3NDORMS, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, 4Eli Lilly and Company, Indianapolis, IN

    Background/Purpose:   Baricitinib, an oral inhibitor of JAK1 and JAK2 activity, was investigated as treatment for patients with moderately to severely active RA despite use…
  • Abstract Number: 1434 • 2013 ACR/ARHP Annual Meeting

    Assessing Janus Kinase inhibitor’s Place In Therapy In Established Rheumatoid Arthritis Patients – From a Simplified Indirect Comparison Versus Tumor Necrosis Factor Inhibitors To a Bayesian Probability Of Response – The Value Of Transparency

    Michael P. Ingham1, Paul Song2, Shannon Cartier3, Karin Lawson-Remer2 and Erin Murray2, 1Janssen Scientific Affairs, LLC, Horsham, PA, 2Doctor Evidence LLC, Santa Monica, CA, 3Optum, Eden Prairie, MN

    Background/Purpose: Bayesian style network meta-analyses and mixed treatment comparisons help address potential bias from effect modifying trial covariates within indirect comparisons and are theoretically easier…
  • Abstract Number: 822 • 2013 ACR/ARHP Annual Meeting

    Inhibition Of Casein Kinase II Reduces TGFβ Induced Fibroblast Activation and Ameliorates Experimental Fibrosis

    Yun Zhang, Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany

    Background/Purpose: Casein kinase-2 (CK2) is a highly conserved serine/threonine kinase. CK2 is a tetramer composed of 2 catalytic subunits (α or α’) and 2 β…
  • Abstract Number: 802 • 2013 ACR/ARHP Annual Meeting

    Tofacitinib, An Oral Janus Kinase Inhibitor: Analysis Of Malignancies Across The Rheumatoid Arthritis Clinical Program

    X. Mariette1, J. R. Curtis2, E. B. Lee3, B. Benda4, I. Kaplan5, K. Soma5, R. Chew5, J. Geier6, L. Wang7 and R. Riese5, 1Paris-Sud University, Paris, France, 2Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, 3Seoul National University, Seoul, South Korea, 4Pfizer Inc, Collegeville, PA, 5Pfizer Inc, Groton, CT, 6Pfizer Inc, New York, NY, 7Pfizer Worldwide R&D, Cambridge, MA

    Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This analysis extended the evaluation of malignancies that occurred…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology